` TTNP (Titan Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

TTNP
vs
S&P 500

Over the past 12 months, TTNP has underperformed S&P 500, delivering a return of -2% compared to the S&P 500's +15% growth.

Stocks Performance
TTNP vs S&P 500

Loading
TTNP
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
TTNP vs S&P 500

Loading
TTNP
S&P 500
Difference
www.alphaspread.com

Performance By Year
TTNP vs S&P 500

Loading
TTNP
S&P 500
Add Stock

Competitors Performance
Titan Pharmaceuticals Inc vs Peers

Titan Pharmaceuticals Inc
Glance View

Market Cap
6.6m USD
Industry
Pharmaceuticals

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. The company is headquartered in South San Francisco, California and currently employs 11 full-time employees. The firm is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.

TTNP Intrinsic Value
Not Available
Back to Top